• HSD3B1 genotype linked to worse outcomes in low-volume metastatic prostate cancer

    7 monthes ago - By Healio

    The adrenal-permissive HSD3B1 genotype appeared associated with earlier castration resistance and shorter OS among men with low-volume metastatic prostate cancer, according to results of a retrospective analysis of a randomized phase 3 study published in JAMA Oncology.
    Genetic testing for the variant may help identify men who are more likely to benefit from escalated androgen receptor axis inhibition beyond gonadal testosterone suppression, researchers noted.
    “These findings lay the groundwork for more personalized and effective treatments for prostate cancer,” Nima Sharifi, MD,
    Read more ...